US · RNTX
Rein Therapeutics Inc.
- Sector
- Healthcare · Medical - Pharmaceuticals
- Headquarters
- Austin, TX 78758
- Website
- reintx.com
Price · as of 2024-12-31
$1.03
Market cap 29.97M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $32.60 | ||||
| 2021 | $8.34 | ||||
| 2022 | $1.30 | ||||
| 2023 | $5.83 | ||||
| 2024 | $1.99 |
AI valuation
Our deep-learning model estimates Rein Therapeutics Inc.'s (RNTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $1.03
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RNTX | Rein Therapeutics Inc. | $1.03 | 29.97M | — | — | — | — | -0.57 | 0.66 | — | -0.81 | -21.57 | 6.09 | 0.00% | — | — | -205.24% | -408.03% | -71.76% | 0.00 | — | 2.38 | 2.24 | 0.46 | 263.00% | — | 1254.00% | -62.45% | -3.88 | -143.12% | 0.00% | 0.00% | 0.00% | -0.35 | -1.02 | — | -8.63 |
| BCAB | BioAtla, Inc. | $0.25 | 14.5M | — | +725% | — | — | -0.24 | 1.17 | 1.52 | 0.43 | — | 1.17 | 91.59% | -672.21% | -634.33% | -164.30% | 204.59% | -81.10% | 0.06 | — | 3.52 | 3.37 | 0.66 | -4419.00% | — | -3091.00% | -429.27% | -4.95 | 199.04% | 0.00% | 0.00% | 0.00% | 0.43 | 0.44 | -2.86 | -16.32 |
| BEAT | HeartBeam, Inc. | $1.51 | 52.01M | — | — | — | — | -3.00 | 35.28 | — | -2.82 | -216.03 | 35.28 | 0.00% | — | — | -221.11% | 4079.38% | -190.60% | 0.00 | — | 1.71 | 1.47 | 0.12 | 139.00% | — | 1881.00% | -25.14% | -8.92 | 3009.64% | 0.00% | 0.00% | 0.00% | -2.81 | -3.82 | — | -22.07 |
| CELU | Celularity Inc. | $1.23 | 29.59M | +3,881% | -60% | — | — | -0.47 | 3.05 | 0.50 | -2.17 | — | -3.47 | 72.36% | -70.75% | -106.77% | -232.51% | -41.90% | -41.86% | 7.79 | -6.12 | 0.38 | 0.27 | -1.56 | -7600.00% | 13811.00% | -8464.00% | -24.37% | -0.12 | -7.17% | 0.00% | 0.00% | 0.00% | -2.48 | -14.48 | 1.75 | -10.21 |
| KZR | Kezar Life Sciences, Inc. | $6.70 | 49.07M | +394% | — | — | — | -5.31 | 3.80 | — | -4.05 | — | 3.80 | 0.00% | — | — | -55.00% | -3029.25% | -45.77% | 0.14 | -56.88 | 6.76 | 6.53 | 0.32 | -1786.00% | -10000.00% | -1104.00% | -16.69% | -3.65 | -2482.15% | 0.00% | 0.00% | 2.03% | -3.63 | -4.43 | — | 4.31 |
| MRSN | Mersana Therapeutics, Inc… | $29.08 | 145.36M | +85% | +9,159% | — | — | -0.96 | -7.01 | 1.65 | 0.62 | — | -7.01 | 95.98% | -181.09% | -170.86% | -505.14% | 57.77% | -37.33% | -3.01 | -18.93 | 2.19 | 2.16 | 1.25 | -6180.00% | 988.00% | -5178.00% | -123.65% | -1.32 | 64.97% | 0.00% | 0.00% | 0.00% | 0.54 | 0.48 | -0.97 | -9.18 |
| NOTV | Inotiv, Inc. | $0.27 | 9.31M | +5,205% | +18% | — | — | -0.38 | 0.19 | 0.05 | 20.53 | — | -0.13 | 12.68% | -6.02% | -13.38% | -44.78% | -3.99% | -8.84% | 3.70 | -0.55 | 0.35 | 0.21 | 19.47 | -4964.00% | 454.00% | -702.00% | -102.98% | -0.02 | -4.47% | 0.00% | 0.00% | 0.00% | -16.44 | -18.77 | 0.99 | -1.15 |
| QNTM | Quantum BioPharma Ltd. | $3.55 | 13.64M | — | — | — | — | -0.35 | 0.46 | — | 0.08 | — | 0.80 | 0.00% | — | — | -120.69% | -212.74% | -86.23% | 0.07 | -339.16 | 1.80 | 1.65 | 0.36 | -5750.00% | — | -3649.00% | -130.92% | -1.03 | -90.66% | 0.00% | 0.00% | 52.41% | 0.07 | 0.16 | — | -16.34 |
| TPST | Tempest Therapeutics, Inc… | $2.28 | 11.23M | — | — | — | — | -7.25 | 15.85 | — | -7.18 | — | 15.85 | 0.00% | — | — | -182.35% | -676.64% | -89.90% | 0.80 | -31.93 | 2.21 | 2.13 | 0.37 | -2147.00% | — | 2156.00% | -11.03% | -2.32 | -538.75% | 0.00% | 0.00% | 0.00% | -6.86 | -8.62 | — | -1.70 |
| YI | 111, Inc. | $7.91 | 68.56M | +302% | -56% | — | — | -25.62 | -0.83 | 0.04 | 13.27 | — | -0.83 | 5.76% | 0.01% | -0.45% | 3.39% | -0.26% | -0.71% | -0.40 | 0.07 | 1.13 | 0.47 | -8.35 | -8386.00% | -366.00% | -15422.00% | 46.56% | 0.11 | -30.18% | 0.00% | 0.00% | 8.50% | 154.56 | 1.32 | 0.02 | 3.48 |
About Rein Therapeutics Inc.
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
- CEO
- James Brian Windsor
- Employees
- 11
- Beta
- 1.50
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.03) − 1 = — (DCF, example).